33 results about "Schistosomiasis japonicum" patented technology

The invention relates to the field of genetic engineering antibody, and builds schistosoma japonicum immature egg soluble antigen (SIEA) single-chain antibody library for the first time. By screening the SIEA single-chain antibody library through an immuno-affinity screening technique, a specific single-chain antibody aiming at anti-schistosomiasis-japonica effective natural molecular vaccine SIEA26-28kDa is obtained. The obtainment of the specific single-chain antibody provides a foundation for treating schistosomiasis japonica, utilizing the specific single-chain antibody as a probe to screen schistosoma japonicum cDNA libraries and obtaining a corresponding gene sequence aiming at anti-schistosomiasis-japonica effective vaccine molecules more conveniently and rapidly.

The invention discloses the application of human β-actin as a serological diagnostic marker for the occurrence of schistosomiasis hepatic fibrosis, and the amino acid sequence of the β-actin protein is shown in SEQ ID NO:1. The study found that in the liver of Schistosoma japonicum hepatic fibrosis mice and patient serum, the gene and protein levels of β-actin were unstable, and its content in the liver increased significantly with the development of fibrosis, and the content in serum increased with the development of fibrosis. The development of fibrosis was significantly reduced. Therefore, the expression level of β-actin has become an important diagnostic index for judging the occurrence of liver fibrosis and the degree of lesion in patients with schistosomiasis japonicum. By detecting the expression level of β-actin in peripheral blood of patients, it can provide more information for field investigation and clinical work. It is a simple, easy-to-operate, economical and scientific diagnostic technique for liver fibrosis in Schistosomiasis japonicum.

The invention discloses a Schistosoma japonicum recombinant antigen, which is produced by expressing a recombinant vector containing a Schistosoma japonicum MRP1 gene fragment. The sequence of the MRP1 gene fragment encodes the amino acid sequence shown in SEQ ID NO.1 Nucleotide sequence. The invention also discloses the application of the above-mentioned schistosomiasis recombinant antigen in the preparation of products for diagnosing schistosomiasis japonicum. The schistosomiasis recombinant antigen rSjMRP1 of the invention is used for diagnosing schistosomiasis, has high sensitivity and strong specificity, and is of great significance for the prevention and treatment of schistosomiasis.

The invention provides application of myricetin in preparation of a drug for treating schistosomiasis. By in-vitro observing an effect of the myricetin for resisting schistosoma japonicum and carryingout in-vivo experiment by establishing a schistosoma japonicum infected mouse model, it is found that the myricetin has good schistosoma japonicum killing effect and an improvement effect on liver fibrosis of schistosoma japonicum infected mice in vivo and in vitro. Moreover, the insecticidal effect of the myricetin is equivalent to that of positive drug praziquantel, the myricetin can replace the application of the positive drug praziquantel to schistosomiasis japonica, possibility is provided for avoiding clinical drug resistance, and the myricetin has a great application prospect.

The invention provides a schistosoma japonicum antigen protein rSjScP92 and an application thereof. A series of genes which are highly expressed in schistosoma japonicum schistosoma are screened by using a schistosoma japonicum schistosoma whole genome expression profile chip, and antigen proteins coded by the genes SjScP15, SjScP57 and SjScP92 can be specifically recognized by serum of a schistosomiasis patient and show a relatively strong positive reaction. ELISA (enzyme-linked immunosorbent assay) detection shows that the antigen proteins have high sensitivity and specificity when being used for detecting the schistosoma japonicum and can be used for developing a schistosoma japonicum disease diagnostic reagent. After mice immunized by the schistosoma japonicum antigen proteins SjScP15, SjScP57 and SjScP92 are attacked by insects, the immune protection effect shows that the SjScP15, the SjScP57 and the SjScP92 are expected to be developed into schistosomiasis vaccines.

The invention provides a gene highly expressed in schistosoma japonicum katsurada, and a coding protein and application thereof. A schistosoma japonicum whole genome expression profile chip is utilized to screen a series of genes highly expressed in schistosoma japonicum katsurada, wherein the antigen proteins coded by the genes SjScP27, SjScP80, SjScP84 and SjScP88 can be specifically recognizedby the serum of a schistosomiasis patient, and have strong positive reaction. The ELISA detection indicates that the antigen proteins have high sensitivity and specificity when being used for detecting schistosoma japonicum, and can be used for developing schistosoma japonicum diagnostic reagents.

The invention discloses a urine biological marker for early diagnosis of schistosomiasis japonica, wherein the urine biological marker is one or more of xanthonic acid, naphthalenesulfonic acid or heptanoylcarnitine. The sensitivity and specificity of the markers were all greater than 0.9, and the area under the curve (AUC) was greater than 0.9, indicating that the three indicators had good predictive performance and could be used for early diagnosis of schistosomiasis japonica. The invention also discloses a screening method for early diagnosis of schistosomiasis japonica urine biomarkers based on metabolomics. By constructing a mouse schistosomiasis japonica model, the ultra-high performance liquid chromatography-tandem mass spectrometry technology is used to metabolize mouse urine. The omics analysis found and analyzed the characteristic differential metabolites between normal mice and Schistosoma japonicum-infected mice, which were biomarkers for early diagnosis of Schistosomiasis japonicum. The screening method has the characteristics of non-invasiveness, convenience and quickness, and can accurately reflect the difference of the metabolic profile between the mice infected with schistosomiasis japonicum and the normal mice, and has high specificity.

The invention relates to the use of ginkgoic acid in preparation of biological pesticide for killing Oncomelania snail and preventing schistosomiasis, wherein experiment result shows that, the ginkgolic acid can effectively inhibit key enzyme and de-coupling reaction to mitochondria oxidation phosphorylation in mollusk energy supply biochemical metabolism, effectively inhibit tyrosinase during insect exuviation procedure and prostaglandin synthetase during breeding process, thus can eradicate unwanted mollusk harming agronomic crops.

The invention discloses a serum biomarker for early diagnosis of schistosomiasis japonicum, and the serum biomarker is phosphatidylcholine and / or palmicholin. The sensitivity and specificity of the markers are both greater than 0.9, and the area under the curve (AUC) is greater than 0.9, indicating that these two indicators have better predictability and can be used for early diagnosis of schistosomiasis japonicum. The invention also discloses a metabolomics-based screening method for serum biomarkers for the early diagnosis of schistosomiasis japonicum, by constructing a mouse schistosomiasis model, and using ultra-high performance liquid chromatography-tandem mass spectrometry to perform metabolomics on mouse serum Analyze, discover and analyze the characteristic differential metabolites between normal mice and Schistosoma japonicum-infected mice, which are biomarkers for early diagnosis of Schistosomiasis japonicum. The screening method has the characteristics of convenience and quickness, can accurately reflect the difference in metabolic spectrum between mice infected with schistosomiasis japonicum and normal mice, and has high specificity.

The present invention discloses Schistosoma japonicum specific male fluke protein and its gene sequence and specifically combined antibody as well as Schistosoma japonicum preventing and treating vaccine prepared with the specific male fluke protein as immunogen and the application of the specific male fluke protein in preparing medicine for preventing and treating Schistosoma japonicum. Applying the specific male fluke protein can inhibit the sexual maturity of female fluke and disturb the pairing of female and male flukes and the ovipositiom of female fluke, so as to treat schistosomiasis and prevent Schistosoma japonicum diffusion.

The invention discloses a molecular detection method for Schistosoma japonicum RPA, which comprises the following steps: 1) designing a pair of specific primers and a probe according to the sequence of the gene of Schistosoma japonicum SjCHGCS19, the nucleotide sequence of the gene of Schistosoma japonicum SjCHGCS19 is as follows: Shown in SEQ ID NO: 1; 2) extract the total DNA in the sample to be tested, and perform isothermal amplification reaction of recombinase polymerase; 3) detect the amplified product. The invention has high specificity and sensitivity for the detection of schistosomiasis japonicum, and can detect schistosomiasis japonicum by sampling feces or whole blood within a short time after animal infection, so it is beneficial to realize early diagnosis and early warning of schistosomiasis japonicum And laboratory early identification and screening.

The invention provides a gene highly expressed in Schistosoma japonicum larvae, its encoded protein and its application. The present invention screens a series of highly expressed genes in Schistosoma japonicum larvae by using the whole genome expression spectrum chip of Schistosoma japonicum, wherein the antigenic proteins encoded by the genes SjScP27, SjScP80, SjScP84, and SjScP88 can be specifically recognized by the serum of schistosomiasis patients, and present strong positive reaction. ELISA detection showed that these antigenic proteins had high sensitivity and specificity in detecting schistosomiasis, and could be used in the development of diagnostic reagents for schistosomiasis japonicum.

The invention provides a gene highly expressed in Schistosoma japonicum larvae, its encoded protein and its application. The present invention screens a series of highly expressed genes in Schistosoma japonicum larvae by using the whole genome expression spectrum chip of Schistosoma japonicum, wherein the antigenic proteins encoded by the genes SjScP27, SjScP80, SjScP84, and SjScP88 can be specifically recognized by the serum of schistosomiasis patients, and present strong positive reaction. ELISA detection showed that these antigenic proteins had high sensitivity and specificity in detecting schistosomiasis, and could be used in the development of diagnostic reagents for schistosomiasis japonicum.

The invention discloses application of a compound with a structural formula (I) in preparation of a drug used for resisting Schistosomiasis japonicum. According to the invention, through deep analysis of the synthetic route of aliphatic acid of Schistosomiasis japonicum, it is believed 3-oxoacyl-ACP reductase (OAR) participating in the synthetic route is a crucial rate-limiting enzyme; on such a basis, target screening of compounds and in vitro insecticidal activity tests are carried out, then inhibition of the selected compound with insecticidal activity on the activity of target protein OAR is analyzed, and finally, toxicity of the active compound on a host cell is assessed. The compound with the structural formula (I) has substantial insecticidal activity and the potential of becoming a lead compound for resistance of Schistosomiasis japonicum and provides a novel approach and means for treatment of Schistosomiasis japonicum.